These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 10473986)

  • 1. Molecular heterogeneity of free PSA in sera of patients with benign and malignant prostate tumors.
    Hilz H; Noldus J; Hammerer P; Buck F; Lück M; Huland H
    Eur Urol; 1999 Oct; 36(4):286-92. PubMed ID: 10473986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Separation of enzymatically active and inactive prostate-specific antigen (PSA) by peptide affinity chromatography.
    Wu P; Stenman UH; Pakkala M; Närvänen A; Leinonen J
    Prostate; 2004 Mar; 58(4):345-53. PubMed ID: 14968435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum free prostate specific antigen: isoenzymes in benign hyperplasia and cancer of the prostate.
    Huber PR; Schmid HP; Mattarelli G; Strittmatter B; van Steenbrugge GJ; Maurer A
    Prostate; 1995 Oct; 27(4):212-9. PubMed ID: 7479388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategy for sensitive and specific detection of molecular forms of PSA based on 2DE and kinetic analysis: a step towards diagnosis of prostate cancer.
    Kumar V; Hassan MI; Singh AK; Dey S; Singh TP; Yadav S
    Clin Chim Acta; 2009 May; 403(1-2):17-22. PubMed ID: 19118539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Molecular forms of prostate-specific antigen and their clinical significance].
    Hilz H
    Urologe A; 1995 Jul; 34(4):275-82. PubMed ID: 7545841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate specific antigen in benign prostatic hyperplasia: purification and characterization.
    Chen Z; Chen H; Stamey TA
    J Urol; 1997 Jun; 157(6):2166-70. PubMed ID: 9146608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of molecular species of prostate-specific antigen complexed with immunoglobulin M in prostate cancer and benign prostatic hyperplasia.
    Goč S; Janković M
    Dis Markers; 2013; 35(6):847-55. PubMed ID: 24367138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
    Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-dimensional electrophoresis of prostate-specific antigen in sera of men with prostate cancer or benign prostate hyperplasia.
    Charrier JP; Tournel C; Michel S; Dalbon P; Jolivet M
    Electrophoresis; 1999; 20(4-5):1075-81. PubMed ID: 10344287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolation and characterization of free form prostate specific antigen (f-PSA) in sera of men with prostate cancer.
    Noldus J; Chen Z; Stamey TA
    J Urol; 1997 Oct; 158(4):1606-9. PubMed ID: 9302183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia.
    Stephan C; Lein M; Jung K; Schnorr D; Loening SA
    Cancer; 1997 Jan; 79(1):104-9. PubMed ID: 8988733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The precursor form of the human kallikrein 2, a kallikrein homologous to prostate-specific antigen, is present in human sera and is increased in prostate cancer and benign prostatic hyperplasia.
    Saedi MS; Hill TM; Kuus-Reichel K; Kumar A; Payne J; Mikolajczyk SD; Wolfert RL; Rittenhouse HG
    Clin Chem; 1998 Oct; 44(10):2115-9. PubMed ID: 9761243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
    Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
    J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization and determination of the complex between prostate-specific antigen and alpha 1-protease inhibitor in benign and malignant prostatic diseases.
    Zhang WM; Finne P; Leinonen J; Stenman UH
    Scand J Clin Lab Invest Suppl; 2000; 233():51-8. PubMed ID: 11317942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential percentage of serum prostate-specific antigen subforms suggests a new way to improve prostate cancer diagnosis.
    Sarrats A; Comet J; Tabarés G; Ramírez M; Aleixandre RN; de Llorens R; Peracaula R
    Prostate; 2010 Jan; 70(1):1-9. PubMed ID: 19670261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum.
    Mikolajczyk SD; Grauer LS; Millar LS; Hill TM; Kumar A; Rittenhouse HG; Wolfert RL; Saedi MS
    Urology; 1997 Nov; 50(5):710-4. PubMed ID: 9372880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of prostate-specific antigen coupled to immunoglobulin M in prostate cancer patients.
    Beneduce L; Prayer-Galetti T; Giustinian AM; Gallotta A; Betto G; Pagano F; Fassina G
    Cancer Detect Prev; 2007; 31(5):402-7. PubMed ID: 18035503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple forms of prostate-specific antigen in serum: differences in immunorecognition by monoclonal and polyclonal assays.
    Zhou AM; Tewari PC; Bluestein BI; Caldwell GW; Larsen FL
    Clin Chem; 1993 Dec; 39(12):2483-91. PubMed ID: 7504592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different glycan structures in prostate-specific antigen from prostate cancer sera in relation to seminal plasma PSA.
    Tabarés G; Radcliffe CM; Barrabés S; Ramírez M; Aleixandre RN; Hoesel W; Dwek RA; Rudd PM; Peracaula R; de Llorens R
    Glycobiology; 2006 Feb; 16(2):132-45. PubMed ID: 16177264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease.
    Mikolajczyk SD; Rittenhouse HG
    Rinsho Byori; 2004 Mar; 52(3):223-30. PubMed ID: 15137320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.